Brief: MAIA Biotechnology Presents Preclinical Data At SITC Annual Meeting Validating Efficacy Of THIO In Treating Hepatocellular Carcinoma
15/11/2022 14:50
Nov 15 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY PRESENTS PRECLINICAL DATA AT SITC
ANNUAL
MEETING VALIDATING EFFICACY OF THIO IN TREATING HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nBw1CsHMsa
Further company coverage: MAIA.A
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale